- Home
- WWR vs CMMB Comparison
WWR vs CMMB Comparison
Compare WWR & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WWR
- CMMB
- Stock Information
- Founded
- WWR 1977
- CMMB 2004
- Country
- WWR United States
- CMMB Israel
- Employees
- WWR N/A
- CMMB N/A
- Industry
- WWR Metal Mining
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- WWR Basic Materials
- CMMB Health Care
- Exchange
- WWR Nasdaq
- CMMB Nasdaq
- Market Cap
- WWR 48.0M
- CMMB 22.0M
- IPO Year
- WWR N/A
- CMMB N/A
- Fundamental
- Price
- WWR $0.70
- CMMB $2.79
- Analyst Decision
- WWR Strong Buy
- CMMB Strong Buy
- Analyst Count
- WWR 2
- CMMB 2
- Target Price
- WWR $2.00
- CMMB $26.50
- AVG Volume (30 Days)
- WWR 1.0M
- CMMB 141.5K
- Earning Date
- WWR 11-14-2025
- CMMB 11-13-2025
- Dividend Yield
- WWR N/A
- CMMB N/A
- EPS Growth
- WWR N/A
- CMMB N/A
- EPS
- WWR N/A
- CMMB N/A
- Revenue
- WWR N/A
- CMMB N/A
- Revenue This Year
- WWR N/A
- CMMB N/A
- Revenue Next Year
- WWR N/A
- CMMB N/A
- P/E Ratio
- WWR N/A
- CMMB N/A
- Revenue Growth
- WWR N/A
- CMMB N/A
- 52 Week Low
- WWR $0.45
- CMMB $2.71
- 52 Week High
- WWR $1.32
- CMMB $9.84
- Technical
- Relative Strength Index (RSI)
- WWR 44.56
- CMMB 20.80
- Support Level
- WWR $0.66
- CMMB $2.70
- Resistance Level
- WWR $0.82
- CMMB $3.09
- Average True Range (ATR)
- WWR 0.04
- CMMB 0.20
- MACD
- WWR -0.01
- CMMB -0.00
- Stochastic Oscillator
- WWR 25.62
- CMMB 8.44
About WWR Westwater Resources Inc.
Westwater Resources Inc focused on developing battery-grade natural graphite materials. The company is having one project which is the Westwater's coosa project which is currently used for the mining and extraction of graphite.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.